Updated Results on Modakafusp Alfa (TAK-573) Safety and Efficacy; Phase 1/2 Study of RRMM Patients

$ 25.50

4.6
(524)
In stock
Description

RVd Alone vs Rvd Plus ASCT in Newly Diagnosed Patients

IMF Patient & Family Webinar 2023 - Understanding The New Myeloma

Results from the first-in-human study of Modakafusp Alfa in Pts

Myeloma Clinical Trials

Updated Results on Modakafusp Alfa (TAK-573) Safety and Efficacy

Congress and Scientific Presentations at ash

ctDNA Analysis and Relapse Association in Primary RRMM Patients

Current Status of Novel Agents for the Treatment of B Cell

IMF Patient & Family Webinar 2023 - Understanding The New Myeloma

RVd Alone vs Rvd Plus ASCT in Newly Diagnosed Patients

Interleukin-Based Treatments Find Footing in Ongoing Research

IMF Patient & Family Webinar 2023 - Understanding The New Myeloma

Frontiers Sustained response in early responders to safinamide